Joseph Lotem

List of Publications by Year
in descending order

35 papers	2,510 citations	304743 22 h-index	377865 34 g-index
35 all docs	35 docs citations	35 times ranked	3023 citing authors

#	Article	IF	Citations
1	Runx3 prevents spontaneous colitis by directing the differentiation of anti-inflammatory mononuclear phagocytes. PLoS ONE, 2020, 15, e0233044.	2.5	13
2	Leo Sachs. 14 October 1924â€"12 December 2013. Biographical Memoirs of Fellows of the Royal Society, 2019, 66, 355-375.	0.1	0
3	Runx3 in Immunity, Inflammation and Cancer. Advances in Experimental Medicine and Biology, 2017, 962, 369-393.	1.6	43
4	The Leo Sachsâ€™ legacy: a pioneerâ€™s journey through hematopoiesis. International Journal of Developmental Biology, 2017, 61, 127-136.	0.6	1
5	Runx3 at the interface of immunity, inflammation and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 131-143.	7.4	69
6	Transcription Factor Runx3 Regulates Interleukin-15-Dependent Natural Killer Cell Activation. Molecular and Cellular Biology, 2014, 34, 1158-1169.	2.3	93
7	Carcinogen-Induced Skin Tumor Development Requires Leukocytic Expression of the Transcription Factor Runx3. Cancer Prevention Research, 2014, 7, 913-926.	1.5	8
8	Runx3-mediated Transcriptional Program in Cytotoxic Lymphocytes. PLoS ONE, 2013, 8, e80467.	2.5	60
9	The False Paradigm of RUNX3 Function as Tumor Suppressor in Gastric Cancer. Journal of Cancer Therapy, 2013, 04, 16-25.	0.4	4
10	Absence of Runx3 expression in normal gastrointestinal epithelium calls into question its tumour suppressor function. EMBO Molecular Medicine, 2011, 3, 593-604.	6.9	42
11	Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. Journal of Experimental Medicine, 2009, 206, 51-59.	8.5	409
12	Human cancers overexpress genes that are specific to a variety of normal human tissues. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18556-18561.	7.1	18
13	Induction in myeloid leukemic cells of genes that are expressed in different normal tissues. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16022-16027.	7.1	11
14	Runx3 regulates mouse TGF-Î²-mediated dendritic cell function and its absence results in airway inflammation. EMBO Journal, 2004, 23, 969-979.	7.8	269
15	Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7731-7736.	7.1	344
16	Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6718-6723.	7.1	22
17	Epigenetics wins over genetics: induction of differentiation in tumor cells. Seminars in Cancer Biology, 2002, 12, 339-346.	9.6	59
18	Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene, 2002, 21, 3284-3294.	5.9	109

#	Article	IF	Citations
19	Spatial and temporal expression pattern of Runx3 (Aml2) and Runx1 (Aml1) indicates non-redundant functions during mouse embryogenesis. Mechanisms of Development, 2001, 109, 413-417.	1.7	177
20	Expression of AML1-d, a short human AML1 isoform, in embryonic stem cells suppresses in vivo tumor growth and differentiation. Cell Death and Differentiation, 1998, 5, 765-773.	11.2	28
21	Regulation of Leukaemic Cells by Interleukin 6 and Leukaemia Inhibitory Factor. Novartis Foundation Symposium, 1992, 167, 80-99.	1.1	1
22	Role of different normal hematopoietic regulatory proteins in the differentiation of myeloid leukemic cells. International Journal of Cancer, 1988, 41, 101-107.	5.1	24
23	Target-cell specificity of hematopoietic regulatory proteins for different clones of myeloid leukemic cells: Two regulators secreted by krebs carcinoma cells. International Journal of Cancer, 1988, 41, 622-628.	5.1	14
24	Review of clinical and haematological response to lowâ€dose cytosine arabinoside in acute myeloid leukaemia. European Journal of Haematology, 1987, 38, 3-11.	2.2	16
25	Independent regulation of myeloid cell growth and differentiation inducing proteins:In vivo regulation by compounds that induce inflammation. International Journal of Cancer, 1985, 35, 93-100.	5.1	18
26	Haematopoietic growth factors. Nature, 1984, 312, 407-407.	27.8	32
27	Control ofin vivo differentiation of myeloid leukemic cells. iv. inhibition of leukemia development by myeloid differentiation-inducing protein. International Journal of Cancer, 1984, 33, 147-154.	5.1	55
28	Coupling of growth and differentiation in normal myeloid precursors and the breakdown of this coupling in leukemia. International Journal of Cancer, 1983, 32, 127-134.	5.1	58
29	Control ofin vivo differentiation of myeloid leukemic cells. III. Regulation By T Lymphocytes And Inflammation. International Journal of Cancer, 1983, 32, 781-791.	5.1	19
30	In vivo inhibition of the development of myeloid leukemia by injection of macrophage-and granulocyte-inducing protein. International Journal of Cancer, 1981, 28, 375-386.	5.1	115
31	Separation of different molecular forms of macrophage- and granulocyte-inducing proteins for normal and leukemic myeloid cells. International Journal of Cancer, 1980, 25, 763-771.	5.1	109
32	Genetic dissociation of different cellular effects of interferon on myeloid leukemic cells. International Journal of Cancer, 1978, 22, 214-220.	5.1	38
33	Control of normal differentiation of myeloid leukemic cells. XII. Isolation of normal myeloid colony-forming cells from bone marrow and the sequence of differentiation to mature granulocytes in normal and D+ myeloid leukemic cells. Journal of Cellular Physiology, 1977, 92, 97-108.	4.1	68
34	Induction of specific changes in the surface membrane of myeloid leukemic cells by steroid hormones. International Journal of Cancer, 1975, 15, 731-740.	5.1	131
35	Control of normal differentiation of myeloid leukemic cells. VI. Inhibition of cell multiplication and the formation of macrophages. Journal of Cellular Physiology, 1975, 85, 587-594.	4.1	33